ES2509115T3 - Combinaciones que contienen indazoles sustituidos con amida como inhibidores de poli(ADP-ribosa) polimerasa (PARP) - Google Patents

Combinaciones que contienen indazoles sustituidos con amida como inhibidores de poli(ADP-ribosa) polimerasa (PARP) Download PDF

Info

Publication number
ES2509115T3
ES2509115T3 ES11157369.7T ES11157369T ES2509115T3 ES 2509115 T3 ES2509115 T3 ES 2509115T3 ES 11157369 T ES11157369 T ES 11157369T ES 2509115 T3 ES2509115 T3 ES 2509115T3
Authority
ES
Spain
Prior art keywords
combination
cancer
inhibitors
treatment
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11157369.7T
Other languages
English (en)
Spanish (es)
Inventor
Jesus Maria Ontoria Ontoria
Rita Scarpeli
Carsten Schultz-Fademrecht
Philip Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD Italia SRL
Original Assignee
MSD Italia SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37809722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2509115(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by MSD Italia SRL filed Critical MSD Italia SRL
Application granted granted Critical
Publication of ES2509115T3 publication Critical patent/ES2509115T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES11157369.7T 2007-01-10 2008-01-08 Combinaciones que contienen indazoles sustituidos con amida como inhibidores de poli(ADP-ribosa) polimerasa (PARP) Active ES2509115T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0700432 2007-01-10
GBGB0700432.8A GB0700432D0 (en) 2007-01-10 2007-01-10 Therapeutic compounds
US92131007P 2007-04-02 2007-04-02
US921310P 2007-04-02

Publications (1)

Publication Number Publication Date
ES2509115T3 true ES2509115T3 (es) 2014-10-17

Family

ID=37809722

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11157369.7T Active ES2509115T3 (es) 2007-01-10 2008-01-08 Combinaciones que contienen indazoles sustituidos con amida como inhibidores de poli(ADP-ribosa) polimerasa (PARP)
ES14176452T Active ES2728199T3 (es) 2007-01-10 2008-01-08 Indazoles sustituidos con amida como inhibidores de poli (ADP-ribosa) polimerasa (PARP)
ES08702101T Active ES2362214T3 (es) 2007-01-10 2008-01-08 Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp).

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES14176452T Active ES2728199T3 (es) 2007-01-10 2008-01-08 Indazoles sustituidos con amida como inhibidores de poli (ADP-ribosa) polimerasa (PARP)
ES08702101T Active ES2362214T3 (es) 2007-01-10 2008-01-08 Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp).

Country Status (21)

Country Link
CN (1) CN101578279B (fr)
AT (1) ATE502933T1 (fr)
CR (1) CR10910A (fr)
DE (1) DE602008005711D1 (fr)
DK (2) DK2109608T3 (fr)
ES (3) ES2509115T3 (fr)
GB (1) GB0700432D0 (fr)
HN (1) HN2009001260A (fr)
HU (1) HUE044513T2 (fr)
LT (1) LT2805945T (fr)
LU (1) LUC00072I2 (fr)
ME (1) ME03481B (fr)
MY (1) MY147789A (fr)
NI (1) NI200900135A (fr)
NZ (1) NZ578256A (fr)
PE (1) PE20081558A1 (fr)
PT (3) PT2109608E (fr)
SI (2) SI2336120T1 (fr)
TW (1) TWI528961B (fr)
UA (1) UA97658C2 (fr)
ZA (1) ZA200903898B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106496187A (zh) * 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
CN106432188A (zh) * 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 一种抗癌药2‑[4‑((3s)‑3‑哌啶基)苯基]‑2h‑吲唑‑7‑甲酰胺的制备方法
CN106432187A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 2‑[4‑(‑3‑哌啶基)苯基]‑2h‑吲唑‑7‑甲酰胺的手性拆分方法
CN106632244A (zh) * 2016-09-30 2017-05-10 陕西科技大学 一种制备抗癌药物Niraparib的新型合成方法
CN106467513A (zh) * 2016-09-30 2017-03-01 陕西科技大学 一种制备Niraparib的合成方法
CN108201537A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种尼拉帕尼缓控释药物组合物及其用途
EP3606523A1 (fr) * 2017-03-27 2020-02-12 Tesaro, Inc. Formulations de niraparib
CN109081828B (zh) * 2017-06-14 2021-03-26 上海时莱生物技术有限公司 聚(adp-核糖)聚合酶抑制剂、制备方法及用途
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
CN108084157A (zh) * 2018-02-12 2018-05-29 安庆奇创药业有限公司 一种尼拉帕尼的合成方法
CN108203404A (zh) * 2018-03-02 2018-06-26 上海博邦医药科技有限公司 (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法
US20240016775A1 (en) 2020-02-24 2024-01-18 Fukang (Shanghai) Health Technology Co., Ltd Anti-coronavirus application of poly adp ribose polymerase inhibitor
CN115611860B (zh) * 2021-07-13 2024-06-11 上海博璞诺科技发展有限公司 合成尼拉帕尼的方法

Also Published As

Publication number Publication date
PE20081558A1 (es) 2008-10-30
DE602008005711D1 (de) 2011-05-05
DK2336120T3 (da) 2014-10-06
HUE044513T2 (hu) 2019-10-28
CN101578279A (zh) 2009-11-11
HN2009001260A (es) 2012-03-26
PT2805945T (pt) 2019-06-06
SI2336120T1 (sl) 2014-10-30
MY147789A (en) 2013-01-31
ZA200903898B (en) 2010-04-28
PT2336120E (pt) 2014-10-01
LT2805945T (lt) 2019-06-25
SI2109608T1 (sl) 2011-07-29
ATE502933T1 (de) 2011-04-15
PT2109608E (pt) 2011-05-30
ES2728199T3 (es) 2019-10-22
DK2109608T3 (da) 2011-07-11
ME03481B (fr) 2020-01-20
UA97658C2 (ru) 2012-03-12
NI200900135A (es) 2010-08-30
TW200836731A (en) 2008-09-16
LUC00072I2 (fr) 2018-07-04
ES2362214T3 (es) 2011-06-29
NZ578256A (en) 2011-12-22
GB0700432D0 (en) 2007-02-21
CR10910A (es) 2010-01-19
TWI528961B (zh) 2016-04-11
CN101578279B (zh) 2013-07-17

Similar Documents

Publication Publication Date Title
ES2548131T3 (es) Sales farmacéuticamente aceptables de 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida
US8071623B2 (en) Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
ES2362214T3 (es) Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp).
ES2524787T3 (es) Derivados de piridazinona como inhibidores de PARP
HK40006670A (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
HK1154386B (en) Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
HK1131137B (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors